An innovative strategy for treating prostate cancer, based on immunotherapy, was developed by Sun et al. [118] using a cationic amphiphilic β-CD to deliver CSF-1R (colony-stimulating factor-1 receptor) siRNA on a prostate cancer-bearing mouse model. The gene discussed is CSF1R; the disease is prostate cancer.